TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phae 2 Efficacy Trial of AV Lotion for the Prevention of Cold Illness in Human Subjects
Brief Summary: The purpose of this of this study is to determine if 3804-250A can prevent the common cold caused by the rhinovirus when applied to the hands. The study will also evaluate whether 3804-250A can prevent rhinovirus infection or common cold illnesses.

The study will also evaluate the safety of 3804-250A.


Options:
A: Arm Label: Group 1 Standard; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2 Enhanced Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Supplemental training, education and hygiene | Arm Label: Group 3 Chlorhexidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gluconate, Other: Supplemental training, education and hygiene | Intervention Type: DRUG; Name: Chlorhexidine gluconate; Assigned to Arm(s): Group 3 Chlorhexidine | Intervention Type: OTHER; Name: Supplemental training, education and hygiene; Assigned to Arm(s): Group 2 Enhanced Standard, Group 3 Chlorhexidine
B: Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3804-250A lotion; Type: EXPERIMENTAL; Interventions: Drug: 3804-250A | Intervention Type: DRUG; Name: 3804-250A; Assigned to Arm(s): 3804-250A lotion
C: Arm Label: RSV group; Type: EXPERIMENTAL; Interventions: Biological: RSV vaccine GSK3003891A | Arm Label: Boostrix group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Boostrix | Intervention Type: BIOLOGICAL; Name: RSV vaccine GSK3003891A; Assigned to Arm(s): RSV group | Intervention Type: BIOLOGICAL; Name: Boostrix; Assigned to Arm(s): Boostrix group
D: Arm Label: 1 and 2 - Adults; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 3A - Seropositive Children; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 3B - Seropositive Children; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: 4A - Seronegative Infants and Children; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 4B - Seronegative Infants and Children; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: 5A - Seronegative Infants and Children; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 5B - Seronegative Infants and Children; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine; Assigned to Arm(s): 1 and 2 - Adults, 3A - Seropositive Children, 4A - Seronegative Infants and Children, 5A - Seronegative Infants and Children | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 3B - Seropositive Children, 4B - Seronegative Infants and Children, 5B - Seronegative Infants and Children

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Analysis of the Impact in the Quality of Life of Patients With Pain Secondary to Osteoporotic Vertebral Fractures Receiving Conservative Treatment Versus Percutaneous Vertebroplasty
Brief Summary: The purpose of this study is to determine whether percutaneous vertebroplasty is able to improve long-term quality of life in patients with pain secondary to osteoporotic vertebral fractures, compared to conventional medical treatment.


Options:
A: Arm Label: Vertebroplasty; Type: EXPERIMENTAL; Interventions: Device: Percutaneous vertebroplasty | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Sham vertebroplasty | Intervention Type: DEVICE; Name: Percutaneous vertebroplasty; Assigned to Arm(s): Vertebroplasty | Intervention Type: PROCEDURE; Name: Sham vertebroplasty; Assigned to Arm(s): Control Group
B: Arm Label: vertebroplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: percutaneous injection of cement into the vertebral body | Arm Label: Medical Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical treatment | Intervention Type: PROCEDURE; Name: percutaneous injection of cement into the vertebral body; Assigned to Arm(s): vertebroplasty | Intervention Type: OTHER; Name: Medical treatment; Assigned to Arm(s): Medical Treatment
C: Arm Label: vertebroplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Kyphoplasty | Arm Label: kyphoplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Kyphoplasty | Intervention Type: PROCEDURE; Name: Kyphoplasty; Assigned to Arm(s): kyphoplasty, vertebroplasty
D: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vertebroplasty | Intervention Type: PROCEDURE; Name: Vertebroplasty; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Analysis of the Impact in the Quality of Life of Patients With Pain Secondary to Osteoporotic Vertebral Fractures Receiving Conservative Treatment Versus Percutaneous Vertebroplasty
Brief Summary: The purpose of this study is to determine whether percutaneous vertebroplasty is able to improve long-term quality of life in patients with pain secondary to osteoporotic vertebral fractures, compared to conventional medical treatment.


Options:
A: Arm Label: vertebroplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Kyphoplasty | Arm Label: kyphoplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Kyphoplasty | Intervention Type: PROCEDURE; Name: Kyphoplasty; Assigned to Arm(s): kyphoplasty, vertebroplasty
B: Arm Label: vertebroplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: percutaneous injection of cement into the vertebral body | Arm Label: Medical Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical treatment | Intervention Type: PROCEDURE; Name: percutaneous injection of cement into the vertebral body; Assigned to Arm(s): vertebroplasty | Intervention Type: OTHER; Name: Medical treatment; Assigned to Arm(s): Medical Treatment
C: Arm Label: Vertebroplasty; Type: EXPERIMENTAL; Interventions: Device: Percutaneous vertebroplasty | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Sham vertebroplasty | Intervention Type: DEVICE; Name: Percutaneous vertebroplasty; Assigned to Arm(s): Vertebroplasty | Intervention Type: PROCEDURE; Name: Sham vertebroplasty; Assigned to Arm(s): Control Group
D: Arm Label: vertebroplasty; Type: EXPERIMENTAL; Interventions: Procedure: percutaneous vertebroplasty | Arm Label: sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: sham procedure | Intervention Type: PROCEDURE; Name: percutaneous vertebroplasty; Assigned to Arm(s): vertebroplasty | Intervention Type: PROCEDURE; Name: sham procedure; Assigned to Arm(s): sham procedure

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Healthy Kids-Houston: An Integrated Community Program for the Prevention of Obesity Among Minority Children
Brief Summary: The collaborative study is to determine the effectiveness of an after-school community-based program to prevent obesity among minority children.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Intervention group
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition and exercise education and coping skills training | Intervention Type: BEHAVIORAL; Name: Nutrition and exercise education and coping skills training; Assigned to Arm(s): Intervention
C: Arm Label: Lifestyle modification; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Kids-Houston program | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Healthy Kids-Houston program; Assigned to Arm(s): Lifestyle modification | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Dose; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise program | Arm Label: High dose; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise program | Intervention Type: BEHAVIORAL; Name: Aerobic exercise program; Assigned to Arm(s): High dose, Low Dose

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Healthy Kids-Houston: An Integrated Community Program for the Prevention of Obesity Among Minority Children
Brief Summary: The collaborative study is to determine the effectiveness of an after-school community-based program to prevent obesity among minority children.


Options:
A: Arm Label: Lifestyle modification; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Kids-Houston program | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Healthy Kids-Houston program; Assigned to Arm(s): Lifestyle modification | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Breakfast Skipping; Type: EXPERIMENTAL; Interventions: Behavioral: Breakfast Skipping | Arm Label: Normal Protein Breakfast Meals; Type: EXPERIMENTAL; Interventions: Behavioral: Normal Protein Breakfast Meals | Arm Label: Protein-rich Breakfast Meals; Type: EXPERIMENTAL; Interventions: Behavioral: Protein-rich Breakfast Meals | Intervention Type: BEHAVIORAL; Name: Breakfast Skipping; Assigned to Arm(s): Breakfast Skipping | Intervention Type: BEHAVIORAL; Name: Normal Protein Breakfast Meals; Assigned to Arm(s): Normal Protein Breakfast Meals | Intervention Type: BEHAVIORAL; Name: Protein-rich Breakfast Meals; Assigned to Arm(s): Protein-rich Breakfast Meals
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Dose; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise program | Arm Label: High dose; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise program | Intervention Type: BEHAVIORAL; Name: Aerobic exercise program; Assigned to Arm(s): High dose, Low Dose
D: Arm Label: Physical activity; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): Physical activity

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized, Double Blind, Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Brief Summary: The purpose of this study is to help us learn more about how to lower the patient's risk of the most common complications after their pancreas operation. After tumors are removed and the remaining part of the pancreas is connected to the intestine or closed, a leakage of pancreatic fluid may occur. This fluid may form an "abscess" (collection of pus) or "fistula" that would need to be drained. A fistula is a persistent leakage of pancreatic fluid that sometimes occurs after pancreatic surgery. Fistulas, leaks, and abscesses are complications that are seen in roughly every 15-20 patients out of every 100 that have pancreas surgeries. Complications like these extend the patient's stay in the hospital after surgery. These complications may require the patient's doctor to perform additional tests or procedures to treat them.

The physical and emotional burden these complications place upon patients, as well as the financial cost to the health care system, can be great. The surgeons at Memorial Sloan-Kettering Cancer Center are conducting a study to determine if a drug, SOM230, can help reduce the rate of these complications. SOM230, also known as Pasireotide, is a drug that has been observed to reduce the rate of similar complications in other studies.

The surgeon would like to compare the effects, good and/or bad, of SOM230 with "placebo" (solution without medication) to see if SOM230 reduces the rate of fistulas, leaks and abscesses.


Options:
A: Arm Label: Early drain removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Postoperative drain removal | Arm Label: Standard drain removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Postoperative drain removal | Intervention Type: PROCEDURE; Name: Postoperative drain removal; Assigned to Arm(s): Early drain removal, Standard drain removal
B: Arm Label: No Drains; Type: EXPERIMENTAL; Interventions: Procedure: No Drains | Arm Label: Drains; Type: EXPERIMENTAL; Interventions: Procedure: Drains | Intervention Type: PROCEDURE; Name: No Drains; Assigned to Arm(s): No Drains | Intervention Type: PROCEDURE; Name: Drains; Assigned to Arm(s): Drains
C: Arm Label: SOM230; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide (SOM230) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Pasireotide (SOM230); Assigned to Arm(s): SOM230 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Closed suction drain; Type: ACTIVE_COMPARATOR; Interventions: Procedure: closed suction drain | Arm Label: Closed gravity drain; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Closed gravity drain | Intervention Type: PROCEDURE; Name: Closed gravity drain; Assigned to Arm(s): Closed gravity drain | Intervention Type: PROCEDURE; Name: closed suction drain; Assigned to Arm(s): Closed suction drain

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in Combination With Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects With Acute Coronary Syndromes
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of various doses of YM150 (the experimental drug) in the prevention of ischemic vascular events in subjects with recent acute coronary syndromes.


Options:
A: Arm Label: Dabigatran 110 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran 110 mg | Arm Label: Dabigatran 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran 150 mg | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: unfractionated heparin | Intervention Type: DRUG; Name: dabigatran 110 mg; Assigned to Arm(s): Dabigatran 110 mg | Intervention Type: DRUG; Name: dabigatran 150 mg; Assigned to Arm(s): Dabigatran 150 mg | Intervention Type: DRUG; Name: unfractionated heparin; Assigned to Arm(s): Unfractionated Heparin
B: Arm Label: 12m DAPT Study Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo & Aspirin | Arm Label: 30m DAPT Study Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin | Intervention Type: DRUG; Name: Placebo & Aspirin; Assigned to Arm(s): 12m DAPT Study Arm | Intervention Type: DRUG; Name: Clopidogrel & Aspirin, Prasugrel & Aspirin; Assigned to Arm(s): 30m DAPT Study Arm
C: Arm Label: BioFreedom™ Drug Coated Stent (DCS); Type: EXPERIMENTAL; Interventions: Device: Biofreedom™ Drug Coated Stent (DCS) | Arm Label: Gazelle™ Bare Metal Coronary Stent (BMS); Type: ACTIVE_COMPARATOR; Interventions: Device: Gazelle™ Bare Metal Coronary Stent (BMS) | Intervention Type: DEVICE; Name: Biofreedom™ Drug Coated Stent (DCS); Assigned to Arm(s): BioFreedom™ Drug Coated Stent (DCS) | Intervention Type: DEVICE; Name: Gazelle™ Bare Metal Coronary Stent (BMS); Assigned to Arm(s): Gazelle™ Bare Metal Coronary Stent (BMS)
D: Arm Label: 1. YM150 Dose V, twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 2. YM150 Dose W, once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 3. YM150 Dose X, twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 4. YM150 Dose Y, once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 5. YM150 Dose Y, twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 6. YM150 Dose Z, once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 7. Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: YM150; Assigned to Arm(s): 1. YM150 Dose V, twice daily, 2. YM150 Dose W, once daily, 3. YM150 Dose X, twice daily, 4. YM150 Dose Y, once daily, 5. YM150 Dose Y, twice daily, 6. YM150 Dose Z, once daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 7. Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Vitamin D to Improve Glucose Metabolism and Reduce Inflammation in Obese Adolescents on a Standard Weight Loss Program
Brief Summary: The investigators' project will study the effects of optimizing the vit D status of obese adolescents on markers of glucose metabolism and inflammation.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ACTION | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: ACTION; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): 2
B: Arm Label: Mot. & Fam. Weight Loss + Online Interv.; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational and Family Weight Loss, Behavioral: Online Intervention | Arm Label: Mot. & Fam. Weight Loss + Online Control; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational and Family Weight Loss, Behavioral: Online Control | Arm Label: Basic Health Educ. & Online Interv.; Type: EXPERIMENTAL; Interventions: Behavioral: Basic Health Education, Behavioral: Online Intervention | Arm Label: Basic Health Educ. & Online Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Health Education, Behavioral: Online Control | Intervention Type: BEHAVIORAL; Name: Motivational and Family Weight Loss; Assigned to Arm(s): Mot. & Fam. Weight Loss + Online Control, Mot. & Fam. Weight Loss + Online Interv. | Intervention Type: BEHAVIORAL; Name: Basic Health Education; Assigned to Arm(s): Basic Health Educ. & Online Control, Basic Health Educ. & Online Interv. | Intervention Type: BEHAVIORAL; Name: Online Intervention; Assigned to Arm(s): Basic Health Educ. & Online Interv., Mot. & Fam. Weight Loss + Online Interv. | Intervention Type: BEHAVIORAL; Name: Online Control; Assigned to Arm(s): Basic Health Educ. & Online Control, Mot. & Fam. Weight Loss + Online Control
C: Arm Label: Mandometer; Type: EXPERIMENTAL; Interventions: Device: Mandometer, Behavioral: Lifestyle | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Mandometer | Intervention Type: DEVICE; Name: Mandometer; Assigned to Arm(s): Control, Mandometer | Intervention Type: BEHAVIORAL; Name: Lifestyle; Assigned to Arm(s): Mandometer
D: Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D 3 cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo pill | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D 3 cholecalciferol; Assigned to Arm(s): Vitamin D

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effectiveness of Physical Activity Monitoring and Distance Counselling in an Occupational Health Setting - a Randomised Controlled Trial (CoAct)
Brief Summary: The CoAct study is investigating a novel lifestyle intervention, aimed at the working population, with daily activity monitoring and distance counseling via telephone and secure web messages. The main purpose of this study is to evaluate the effectiveness of lifestyle counseling on the level of physical activity in an occupational health setting. The purposes include also analyzing the potential effects of changes in physical activity on productivity at work and sickness absence, and health care costs.


Options:
A: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Activity monitoring and distance counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Activity monitoring and distance counseling | Intervention Type: BEHAVIORAL; Name: Activity monitoring and distance counseling; Assigned to Arm(s): Activity monitoring and distance counseling
B: Arm Label: MSU; Type: EXPERIMENTAL; Interventions: Procedure: MSU | Arm Label: OCCM; Type: ACTIVE_COMPARATOR; Interventions: Procedure: OCCM | Intervention Type: PROCEDURE; Name: MSU; Assigned to Arm(s): MSU | Intervention Type: PROCEDURE; Name: OCCM; Assigned to Arm(s): OCCM
C: Arm Label: Arm 1 Physical Activity counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Counseling | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Activity Counseling; Assigned to Arm(s): Arm 1 Physical Activity counseling
D: Arm Label: A, 1, I; Type: EXPERIMENTAL; Interventions: Device: Home blood pressure tele-management system. | Arm Label: A, 2, I; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care. | Intervention Type: DEVICE; Name: Home blood pressure tele-management system.; Assigned to Arm(s): A, 1, I | Intervention Type: OTHER; Name: Usual care.; Assigned to Arm(s): A, 2, I

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension
Brief Summary: To test whether the current custom of initiating treatment for hypertension with a single drug is less effective in the short-term than initial combination therapy, and results in the eventual need for comparatively more antihypertensive drug therapy.


Options:
A: Arm Label: Chlorthalidone plus amiloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorthalidone plus amiloride | Arm Label: losartan; Type: EXPERIMENTAL; Interventions: Drug: losartan | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): losartan | Intervention Type: DRUG; Name: Chlorthalidone plus amiloride; Assigned to Arm(s): Chlorthalidone plus amiloride
B: Intervention Type: DRUG; Name: Delapril, Delapril-Manidipine Fixed combination; Assigned to Arm(s): N/A
C: Arm Label: A-1, B-1; Type: ACTIVE_COMPARATOR; Interventions: Drug: trandolapril | Arm Label: A-2, B-2; Type: ACTIVE_COMPARATOR; Interventions: Drug: trandolapril/verapamil | Arm Label: A-3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: A-4; Type: ACTIVE_COMPARATOR; Interventions: Drug: verapamil | Intervention Type: DRUG; Name: trandolapril; Assigned to Arm(s): A-1, B-1 | Intervention Type: DRUG; Name: trandolapril/verapamil; Assigned to Arm(s): A-2, B-2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A-3 | Intervention Type: DRUG; Name: verapamil; Assigned to Arm(s): A-4
D: Arm Label: Combination Therapy; Type: EXPERIMENTAL; Interventions: Drug: Losartan and hydrochlorothiazide | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrochlorothiazide switched over with Losartan at 8 weeks | Intervention Type: DRUG; Name: Losartan and hydrochlorothiazide; Assigned to Arm(s): Combination Therapy | Intervention Type: DRUG; Name: Hydrochlorothiazide switched over with Losartan at 8 weeks; Assigned to Arm(s): Monotherapy

Answer: D